CD20 as a target for therapeutic type i and ii monoclonal antibodies

Seminars in Hematology

Volumn 47, Issue 2, 2010, Pages 107-114

  Beers, Stephen A ^a   Chan, Claude H T ^a   French, Ruth R ^a   Cragg, Mark S ^a   Glennie, Martin J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; FLUDARABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OFATUMUMAB; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE CONTROL; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; INTERNALIZATION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD20; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CALCIUM SIGNALING; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; PROTEIN CONFORMATION; PROTEIN TRANSPORT;

EID: 77950331000     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.001     Document Type: Article

References (59)

1. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125:1678-1685.
2. Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994, 15:450-454.
3. Nadler L.M., Ritz J., Hardy R., Pesando J.M., Schlossman S.F., Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981, 67:134-140.
4. Oettgen H.C., Bayard P.J., Van Ewijk W., Nadler L.M., Terhorst C.P. Further biochemical studies of the human B-cell differentiation antigens B1 and B2. Hybridoma 1983, 2:17-28.
5. Ishibashi K., Suzuki M., Sasaki S., Imai M. Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. Gene 2001, 264:87-93.
6. Liang Y., Buckley T.R., Tu L., Langdon S.D., Tedder T.F. Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics 2001, 53:357-368.
7. Tedder T.F., Streuli M., Schlossman S.F., Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988, 85:208-212.
8. Polyak M.J., Tailor S.H., Deans J.P. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998, 161:3242-3248.
9. Ernst J.A., Li H., Kim H.S., Nakamura G.R., Yansura D.G., Vandlen R.L. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005, 44:15150-15158.
10. Tedder T.F., Schlossman S.F. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 1988, 263:10009-10015.
11. Clark E.A., Shu G.L., Luscher B., et al. Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol 1989, 143:3873-3880.
12. Teeling J.L., Mackus W.J., Wiegman L.J., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177:362-371.
13. Polyak M.J., Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002, 99:3256-3262.
14. Du J., Yang H., Guo Y., Ding J. Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009, 46:2419-2423.
15. Du J., Wang H., Zhong C., et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007, 282:15073-15080.
16. Polyak M.J., Li H., Shariat N., Deans J.P. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008, 283:18545-18552.
17. Li H., Ayer L.M., Polyak M.J., et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004, 279:19893-19901.
18. Polyak M.J., Ayer L.M., Szczepek A.J., Deans J.P. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia 2003, 17:1384-1389.
19. Szollosi J., Horejsi V., Bene L., Angelisova P., Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996, 157:2939-2946.
20. Leveille C., AL-Daccak R., Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999, 29:65-74.
21. Petrie R.J., Deans J.P. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 2002, 169:2886-2891.
22. Walshe C.A., Beers S.A., French R.R., et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 2008, 283:16971-16984.
23. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics 1998, 48:125-132.
24. Uchida J., Lee Y., Hasegawa M., et al. Mouse CD20 expression and function. Int Immunol 2004, 16:119-129.
25. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993, 121:1121-1132.
26. Kanzaki M., Shibata H., Mogami H., Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995, 270:13099-13104.
27. Li H., Ayer L.M., Lytton J., Deans J.P. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003, 278:42427-42434.
28. Golay J.T., Clark E.A., Beverley P.C. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985, 135:3795-3801.
29. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
30. Deans J.P., Robbins S.M., Polyak M.J., Savage J.A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998, 273:344-348.
31. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies-historical and future perspectives. Haematologica 2010, 95:135-143.
32. Cragg M.S., Morgan S.M., Chan H.T., et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
33. Chan H.T., Hughes D., French R.R., et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003, 63:5480-5489.
34. Ivanov A., Beers S.A., Walshe C.A., et al. Homotypic adhesion and lysosome-mediated cell death evoked by anti-CD20 (tositumomab) and HLA DR monoclonal antibodies. J Clin Invest 2009, 119.
35. Ivanov A., Krysov S., Cragg M.S., Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008, 14:4925-4934.
36. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
37. Umana P. New glycoengineered antibodies with enhanced effector functions. Keystone Symposia Abstract. Antibodies as Drugs March 27-April 1, 2009, Whistler, BC, Canada.
38. Ghetie M.A., Bright H., Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001, 97:1392-1398.
39. Goldenberg D.M., Rossi E.A., Stein R., et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009, 113:1062-1070.
40. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171:1581-1587.
41. Golay J., Cittera E., Di Gaetano N., et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.
42. Hamaguchi Y., Uchida J., Cain D.W., et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005, 174:4389-4399.
43. Minard-Colin V., Xiu Y., Poe J.C., et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008, 112:1205-1213.
44. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669.
45. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
46. Beers S.A., Chan C.H., James S., et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008, 112:4170-4177.
47. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., Tedder T.F. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006, 203:743-753.
48. Li Y., Williams M.E., Cousar J.B., Pawluczkowycz A.W., Lindorfer M.A., Taylor R.P. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007, 179:4263-4271.
49. Racila E., Link B.K., Weng W.K., et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008, 14:6697-6703.
50. Wang S.Y., Racila E., Taylor R.P., Weiner G.J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456-1463.
51. Wang S.Y., Veeramani S., Racila E., et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
52. Jilani I., O'Brien S., Manshuri T., et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003, 102:3514-3520.
53. Michel R.B., Mattes M.J. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002, 8:2701-2713.
54. Press O.W., Appelbaum F., Ledbetter J.A., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69:584-591.
55. Cragg M.S., Bayne M.C., Illidge T.M., Valerius T., Johnson P.W., Glennie M.J. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004, 103:3989-3990.
56. Austin C.D., De Maziere A.M., Pisacane P.I., et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004, 15:5268-5282.
57. Tefferi A., Bartholmai B.J., Witzig T.E., Li C.Y., Hanson C.A., Phyliky R.L. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1996, 106:457-461.
58. Beum P.V., Kennedy A.D., Williams M.E., Lindorfer M.A., Taylor R.P. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-2609.
59. Lin T.S., Lucas M.S., Byrd J.C. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003, 30:483-492.